Although FCM is used extensively for this application, standardization is very much in its infancy. 7 Following procedures described by György et al, 1 artificial, insoluble ICs were created, cell-derived MPs were isolated from the serum of healthy donors after an established protocol. 6 Both samples were analyzed by FCM and Dynamic Light Scatter (DLS). In addition, György et al proposed antibody aggregation of certain antibodies leads to microvesicle-mimicking signals. 2 We followed procedures as described 2 to investigate the signal of antibody aggregate versus MPs.
As the DLS data shows ( Figure 1A) , the MPs and ICs overlap in size, but when analyzed by FCM the populations are distinct ( Figure 1B ). In addition, we did not see antibody aggregates produce a microvesicle-mimicking signal, but they did coincide with the IC population ( Figure 1C ), which is not unexpected based on the comparable constituents. For personal use only. on April 8, 2017. by guest www.bloodjournal.org From Following the protocol from Amabile et al, 3 who propose systematic triton lysis as a control to prove the vesicular nature of the MP population, we agree that the use of triton lysis can be a validating step for many MP-IC applications by FCM, as we also saw MP population dissolve from the MP gate. However, using the triton lysis we observed an impact on the IC population (data not shown). Under our conditions, as both populations are distinguishable by light scatter alone, the use of triton lysis in this instance added an unnecessary and complicating step.
Here we have shown that MPs and ICs do not share biophysical light scatter properties when analyzed by FCM, but because of the small size of both, and the limits of some FCM instruments, maintenance, and operation, they may not appear discrete. To the editor:
Ruxolitinib inhibits transforming JAK2 fusion proteins in vitro and induces complete cytogenetic remission in t(8;9)(p22;p24)/PCM1-JAK2-positive chronic eosinophilic leukemia
The JAK1/JAK2 inhibitor ruxolitinib was recently approved for intermediate and high-risk myelofibrosis. However, for malignancies with JAK2 rearrangements, known for their rapid evolution and dismal prognosis, the potential of JAK inhibitor therapy is not established. 1 We investigated the efficacy of ruxolitinib against JAK2 fusions in vitro and in a patient with t(8;9)(p22;p24)/PCM1-JAK2 chronic eosinophilic leukemia (CEL). A 72-year-old male presented with leukocytosis of 49 ϫ 10 9 /L, absolute eosinophil count of 23 ϫ 10 9 /L and circulating myeloid progenitors. Specific symptoms were absent and clinical examination was unremarkable. Bone marrow aspirate and biopsy were hypercellular with prominent myelopoiesis, pronounced eosinophilia, and hypergranulated granulocyte precursors ( Figure 1A) . Cytogenetics showed 46,XY,t(8;9)(p22;p24) in 33 of 35 metaphases, and FISH confirmed the breakpoints in 8p22 (PCM1) and 9p24 (JAK2; Figure 1B ). RT-PCR and Sanger sequencing showed an in-frame fusion between PCM1 exon 36 and JAK2 exon 9, as in the first case reported. 2 This PCM1-JAK2 fusion was cloned and additional ETV6-JAK2 and SEC31A-JAK2 constructs were generated. In Ba/F3 cells, PCM1-JAK2, ETV6-JAK2, and SEC31A-JAK2 induced growthfactor independent growth, [3] [4] [5] which was suppressed by ruxolitinib with IC 50 values of 57, 46, and 92nM, respectively ( Figure 1C ). Western blotting showed dose-dependent inhibition of phosphorylation of JAK2, indicating a direct and specific action of ruxolitinib, and of downstream STAT5 ( Figure 1C ). For comparison, the growth of JAK2-V617F-expressing Ba/F3 was inhibited with 106nM as IC 50 , in line with published data. 5, 6 Similar data were obtained for JAK inhibitor I, a JAK1/JAK2/JAK3/TYK2 inhibitor (not shown).
Given this, and lacking effective medical treatment options, ruxolitinib was initiated after approval from the ethical committee and patient informed consent. Since diagnosis, the leukocyte count had been controlled with hydroxyurea 250-2000 mg/d, but the peripheral eosinophilia remained elevated. Multiple transfusions and dose adjustments were required for anemia, with corresponding fluctuations in leucocytes and eosinophils. After 15 months, ruxolitinib was started at 10 mg twice daily. At this point, 25 of 30 marrow metaphases were t(8;9)-positive ( Figure 1D -E). Ruxolitinib was cautiously increased to 15-20 mg bid and hydroxyurea could be discontinued 6 months later. By then, the eosinophil count had normalized, and the thrombocytopenia partially recovered. Moreover, the number of t(8;9) metaphases had decreased to 10 of 30. Continuing ruxolitinib as single agent, the eosinophil count remained normal. Marrow examinations after 11 and 15 months ruxolitinib therapy were hypocellular without evidence of CEL. After 15 months, a complete cytogenetic response (0 abnormal of 26 analyzed metaphases) was reached; and the number of interphase nuclei with a JAK2/ 9p24 breakpoint in FISH had equally decreased to less than 5%.
